PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma

Inclusion Criteria: * Histological or cytological diagnosis of lymphoepithelioma-like carcinoma * Failed the first-line standard treatment or progressed after the treatment, at least one measurable lesion according to the RECIST1.1 standard * Age between 18 and 80 years old * Estimated life expectancy exceeds 3 months * ECOG Performance Status score ≤ 2 * Normal bone marrow, liver, kidney, clotting function, including： hemoglobin ≥90g/L (no history of blood transfusion within 7 days), absolute neutrophil count ≥1.5×109/L, platelet ≥100×109/L, total bilirubin ≤1.5×ULN, albumin ≥30g/ L, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN), if combined with liver metastases, AST and ALT ≤ 5 × ULN; creatinine ≤ 1.5 × ULN; international standardized ratio (INR) or coagulation Proenzyme time (PT) ≤ 1.5 × ULN, if the subject receives anticoagulant therapy normally, as long as the PT is within the range planned by the anticoagulant drug * Women of childbearing age should have a urine or serum pregnancy test negative within 3 days before receiving the first study drug administration. If the urine pregnancy test result cannot be confirmed negative, a blood pregnancy test is required * Ensure effective contraception during the study period and at least 6 months after the study ended. * Sign an informed consent form and follow up with good compliance Exclusion Criteria: * Merging other pathological tumors * Active bleeding, active diverticulitis, abdominal abscess, gastrointestinal perforation, gastrointestinal obstruction, and peritoneal metastasis that require clinical intervention; clinically uncontrollable pleural, abdominal, and pericardial effusions (drainage effusions are not required or patients who have stopped draining for 3 days without a significant increase in effusion can be enrolled); severe bleeding tendency or coagulopathy；receiving thrombolytic therap * Uncontrolled hypertension（systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg after optimal medical treatment）；history of hypertension crisis or hypertensive encephalopathy * History of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation) * Grade III-IV congestive heart failure (according to New York Heart Association classification), poorly controlled and clinically significant * Any arterial, venous thrombosis, embolism, or ischemia occurred within 6 months before enrolling in the treatment * Central nervous system metastasis * Active infection that requires treatment, or systemic anti-infective drugs have been used within one week before the first dose; or there is active tuberculosis (TB), normal anti-TB treatment or anti-TB within 1 year before the first dose treatment * Known history of human immunodeficiency virus (HIV) infection (ie HIV1/2 antibody positive), known syphilis infection * Acute or chronic active hepatitis B or hepatitis C infection, including hepatitis B virus (HBV) DNA\>2000IU/ml or 104 copies/ml，hepatitis C virus (HCV) RNA\>103 copies/ml or HBsAg Positive simultaneously with anti-HCV antibody * Active autoimmune diseases requiring systemic treatment occurred within 2 years before the first dose(alternative therapies such as thyroxine, insulin, or physiological doses of corticosteroids used for adrenal or pituitary insufficiency are not considered systemic treatment） * History of non-infectious pneumonia requiring corticosteroid therapy or current pneumonia within 1 year before the first dose（patients with intermittent use of bronchodilators, inhaled corticosteroids, or local injection of corticosteroids due to COPD and asthma can be enrolled） * Previously received immunotherapy treatment, or received immunomodulatory drug treatment within 2 weeks before the first dose, or received major surgical treatment within 3 weeks before the first dose * Known to have an allergic reaction to the active ingredient of PD-1 monoclonal antibody and/or any excipients * Mental illnesses or drug abuse that may affect compliance with research requirements * Currently participating in interventional clinical research treatment, or receiving other research drugs or research equipment within 4 weeks before the first dose * Women who are pregnant or breastfeeding * Other acute, chronic and mental diseases that may lead to the following results: laboratory test values are abnormal；increase the risk of research participation or study drug administration； interfere with the interpretation of the study results